4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0000950170-24-077029
Chief Operating Officer sold 39,950 shares at an average $35.09 ($1,401,902)
- Chief Operating Officer acquired 39,950 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| HIGH SUSANNA GATTI Chief Operating Officer | 2024-06-21 | Option exercise 10b5-1 | +29,787 | $5.54 | $165,020 | 178,579 | D |
| HIGH SUSANNA GATTI Chief Operating Officer | 2024-06-21 | Sale 10b5-1 | −29,787 | $35.01 | $1,042,843 | 148,792 | D |
| HIGH SUSANNA GATTI Chief Operating Officer | 2024-06-24 | Option exercise 10b5-1 | +10,163 | $5.54 | $56,303 | 158,955 | D |
| HIGH SUSANNA GATTI Chief Operating Officer | 2024-06-24 | Sale 10b5-1 | −10,163 | $35.33 | $359,059 | 148,792 | D |
| Derivatives | |||||||
| HIGH SUSANNA GATTI Chief Operating Officer | 2024-06-21 | Option exercise · Stock option (right to buy) 10b5-1 | −29,787 | 70,699 | D | ||
| HIGH SUSANNA GATTI Chief Operating Officer | 2024-06-24 | Option exercise · Stock option (right to buy) 10b5-1 | −10,163 | 60,536 | D | ||
| Open-market sales · 39,950 sh · avg $35.09 · $1,401,902 | |||||||
Loading xslF345X05/ownership.xml…